ACE2 and Recurrent upper respiratory tract infections: Our study on ACE2 provides a systematic road map to redesigning an entry receptor as a therapeutic, and we believe the same strategy could be applied to other entry receptors such as DPP4 for treating MERS and ANPEP for treating upper respiratory tract infections by HCoV-229E (42, 51).